Performance of ROIV Roivant Sciences | 22.2% in 12m
Compare ROIV with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Roivant Sciences with its related Sector/Index XBI
Performance Duell ROIV vs XBI
| TimeFrame | ROIV | XBI |
|---|---|---|
| 1 Day | -1.07% | -0.94% |
| 1 Week | -4.05% | -2.69% |
| 1 Month | 1.74% | -0.01% |
| 3 Months | 2.39% | -5.33% |
| 6 Months | 23.0% | 31.03% |
| 12 Months | 22.2% | 3.19% |
| YTD | -1.94% | -2.32% |
| Rel. Perf. 1m | 0.20 | |
| Rel. Perf. 3m | -0.04 | |
| Rel. Perf. 6m | -0.19 | |
| Rel. Perf. 12m | 1.75 |
Is Roivant Sciences a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Roivant Sciences (NASDAQ:ROIV) is currently (May 2024)
not a good stock to buy. It has a ValueRay Fundamental Rating of -45.29 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ROIV as of May 2024 is 10.06. This means that ROIV is currently overvalued and has a potential downside of -9.61% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ROIV as of May 2024 is 10.06. This means that ROIV is currently overvalued and has a potential downside of -9.61% (Sold with Premium).
Is ROIV a buy, sell or hold?
- Strong Buy: 7
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
Values above 0%: ROIV is performing better - Values below 0%: ROIV is underperforming
Compare ROIV with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -4.88% | -0.22% | 3.81% | -6.21% |
| US NASDAQ 100 | QQQ | -4.46% | 0.88% | 5.34% | -14.74% |
| US Dow Jones Industrial 30 | DIA | -5.78% | -2.34% | 6.88% | 1.27% |
| German DAX 40 | DBXD | -7.16% | -2.65% | 1.04% | 4.71% |
| UK FTSE 100 | ISFU | -5.33% | -4.65% | 5.05% | 8.81% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -3.81% | -4.96% | 20.33% | 30.66% |
| Hongkong Hang Seng | HSI | -6.46% | -13.10% | 19.07% | 30.98% |
| Japan Nikkei 225 | EXX7 | -1.45% | 6.69% | 10.15% | 8.61% |
| India NIFTY 50 | INDA | -2.14% | 2.32% | 7.33% | -2.39% |
| Brasil Bovespa | EWZ | -1.82% | 0.65% | 21.74% | 9.62% |
ROIV Roivant Sciences vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -4.65% | 1.17% | 2.65% | -16.08% |
| Consumer Discretionary | XLY | -3.10% | 1.18% | 12.67% | 0.76% |
| Consumer Staples | XLP | -6.29% | -4.04% | 9.10% | 18.58% |
| Energy | XLE | -4.62% | 4.13% | 9.31% | -1.46% |
| Financial | XLF | -5.90% | -2.68% | -1.63% | -11.30% |
| Health Care | XLV | -5.60% | -1.63% | 9.00% | 11.76% |
| Industrial | XLI | -5.40% | -0.52% | -0.52% | -7.59% |
| Materials | XLB | -6.02% | -0.40% | 2.83% | 2.16% |
| Real Estate | XLRE | -6.16% | 0.21% | 10.16% | 16.59% |
| Technology | XLK | -4.35% | 1.68% | 7.37% | -15.10% |
| Utilities | XLU | -7.70% | -9.27% | 1.28% | 15.37% |
| Aerospace & Defense | XAR | -4.37% | -4.57% | 6.67% | -4.80% |
| Biotech | XBI | -1.36% | 1.75% | -8.05% | 18.98% |
| Homebuilder | XHB | -4.66% | -1.40% | -16.73% | -30.97% |
| Retail | XRT | -4.18% | -1.74% | -3.03% | -2.04% |
Does Roivant Sciences outperform its market, is ROIV a Sector Leader?
Yes, over the last 12 months Roivant Sciences (ROIV) made 22.17%, while its related Sector, the SPDR S&P Biotech (XBI) made 3.19%.
Over the last 3 months ROIV made 2.39%, while XBI made -5.33%.
Yes, over the last 12 months Roivant Sciences (ROIV) made 22.17%, while its related Sector, the SPDR S&P Biotech (XBI) made 3.19%.
Over the last 3 months ROIV made 2.39%, while XBI made -5.33%.
| Period | ROIV | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 1.74% | -0.01% | 1.96% |
| 3 Months | 2.39% | -5.33% | 4.29% |
| 12 Months | 22.17% | 3.19% | 28.38% |